Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription 20.10.2025 1 BMC Cancer 1 Cancer Res 2 Eur J Obstet Gynecol Reprod Biol 1 Int J Cancer 1 J Clin Oncol 1 Obstet Gynecol 1 Oncogene 1 Oncol Rep 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. JIAO H, Tian J, Liu Q, Jiang M, et al
   Analysis of FNDC1 as a diagnostic marker and potential therapeutic target for ovarian serous cancer.
   BMC Cancer. 2025;25:1595.
   PubMed         Abstract available
   
   

   
   Cancer Res

2. CARDENAS H, Wang Y, Zhao G, Hao DX, et al
   Metabolic Dependency on De Novo Pyrimidine Synthesis is a Targetable Vulnerability in Platinum Resistant Ovarian Cancer.
   Cancer Res. 2025 Oct 15. doi: 10.1158/0008-5472.CAN-25-0043.
   PubMed         Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

3. SIEGLER Y, Omer A, Yousef Y, Ben David C, et al
   Timing matters: Surgery-to-chemotherapy interval and outcomes in ovarian cancer.
   Eur J Obstet Gynecol Reprod Biol. 2025;315:114772.
   PubMed         Abstract available
   
   
4. GARG M, Bhati P, Nair IR, Sheejamol VS, et al
   Delineating the clinico-oncological landscape: Pure Uterine Serous Cancer (P-USC) versus p53 Abnormal Grade 3-Endometrioid-Endometrial Carcinoma (p53 Abn G3-EEC).
   Eur J Obstet Gynecol Reprod Biol. 2025;314:114696.
   PubMed         Abstract available
   
   

   
   Int J Cancer

5. HERNANDEZ-BERNAL F, Bernal KS, Bequet-Romero M, Martin-Bauta Y, et al
   HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results.
   Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70199.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

6. BANERJEE SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, et al
   Erratum: Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
   J Clin Oncol. 2025 Oct 13:JCO2502377. doi: 10.1200/JCO-25-02377.
   PubMed        
   
   

   
   Obstet Gynecol

7. FILIPPOVA OT, Chi DS, Iasonos A, Abu-Rustum NR, et al
   A Feasibility Study for Mapping Ovarian Sentinel Lymph Nodes: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
   Obstet Gynecol. 2025 Oct 2. doi: 10.1097/AOG.0000000000006077.
   PubMed         Abstract available
   
   

   
   Oncogene

8. WU L, Wu C, He S, Chen Y, et al
   METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
   Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
   PubMed         Abstract available
   
   

   
   Oncol Rep

9. LI T, Xue H, Guo Y, Guo K, et al
   [Expression of Concern] CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
   Oncol Rep. 2026;55:3.
   PubMed         Abstract available
   
   

   
   PLoS One

10. ZHAO X, Kong W, Jiang Y, Sui F, et al
    Current and future burden of gynecological cancers attributable to high body-mass index: A comprehensive global analysis and projection study.
    PLoS One. 2025;20:e0333281.
    PubMed         Abstract available
    
    
11. ZHANG Z, Li Y, Huang H, Wei T, et al
    Disparities and trends of the incidence and mortality of female-specific cancers in the United States.
    PLoS One. 2025;20:e0334128.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.